Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Receivables - Net: 2020-2024

  • Janux Therapeutics' Receivables - Net was N/A to $7.5 million in Q2 2024 from the same period last year, while for Jun 2024 it was $7.5 million, marking a year-over-year change of. This contributed to the annual value of $8.0 million for FY2020, which is N/A change from last year.
  • Janux Therapeutics' Receivables - Net amounted to $7.5 million in Q2 2024, which was up 1,345.09% from $519,000 recorded in Q1 2024.
  • In the past 5 years, Janux Therapeutics' Receivables - Net registered a high of $8.0 million during Q4 2020, and its lowest value of $400,000 during Q2 2021.
  • For the 3-year period, Janux Therapeutics' Receivables - Net averaged around $2.3 million, with its median value being $659,500 (2023).
  • Data for Janux Therapeutics' Receivables - Net shows a maximum YoY slumped of 35.12% (in 2024) over the last 5 years.
  • Over the past 5 years, Janux Therapeutics' Receivables - Net (Quarterly) stood at $8.0 million in 2020, then reached $400,000 in 2021, then reached $500,000 in 2022, then reached $800,000 in 2023, then slumped by 35.12% to $7.5 million in 2024.
  • Its Receivables - Net was $7.5 million in Q2 2024, compared to $519,000 in Q1 2024 and $800,000 in Q1 2023.